Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.
Okuda DT, Kantarci O, Lebrun-Frénay C, Sormani MP, Azevedo CJ, Bovis F, Hua LH, Amezcua L, Mowry EM, Hotermans C, Mendoza J, Walsh JS, von Hehn C, Vargas WS, Donlon S, Naismith RT, Okai A, Pardo G, Repovic P, Stüve O, Siva A, Pelletier D. Okuda DT, et al. Among authors: amezcua l. Ann Neurol. 2023 Mar;93(3):604-614. doi: 10.1002/ana.26555. Epub 2022 Dec 10. Ann Neurol. 2023. PMID: 36401339 Clinical Trial.
MS in self-identified Hispanic/Latino individuals living in the US.
Amezcua L, Oksenberg JR, McCauley JL. Amezcua L, et al. Mult Scler J Exp Transl Clin. 2017 Sep 25;3(3):2055217317725103. doi: 10.1177/2055217317725103. eCollection 2017 Jul-Sep. Mult Scler J Exp Transl Clin. 2017. PMID: 28979795 Free PMC article. Review.
Vitamin D levels in Hispanics with multiple sclerosis.
Amezcua L, Chung RH, Conti DV, Langer-Gould AM. Amezcua L, et al. J Neurol. 2012 Dec;259(12):2565-70. doi: 10.1007/s00415-012-6537-z. Epub 2012 May 16. J Neurol. 2012. PMID: 22588255
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).
Okai AF, Amezcua L, Berkovich RR, Chinea AR, Edwards KR, Steingo B, Walker A, Jacobs AK, Daizadeh N, Williams MJ; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Okai AF, et al. Among authors: amezcua l. Neurol Ther. 2019 Dec;8(2):367-381. doi: 10.1007/s40120-019-00159-2. Epub 2019 Oct 25. Neurol Ther. 2019. PMID: 31654272 Free PMC article.
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD; SPI2 investigative teams. Cree BAC, et al. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. Epub 2020 Oct 23. Lancet Neurol. 2020. PMID: 33222767 Clinical Trial.
Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology.
Hua LH, Obeidat AZ, Amezcua L, Cohen JA, Costello K, Dunn J, Gelfand JM, Goldman MD, Hopkins S, Jeffery D, Krieger S, Newsome SD, Shah S, Sicotte NL, Yadav V, Longbrake EE. Hua LH, et al. Among authors: amezcua l. Neurol Clin Pract. 2021 Aug;11(4):352-357. doi: 10.1212/CPJ.0000000000001040. Neurol Clin Pract. 2021. PMID: 34484933 Free PMC article.
78 results